A son diviersis opzions di cure disponibilis pal tumôr de prostate, a seconde de fase e de agressivitât dal tumôr, cussì come de salût gjenerâl e des preferencis personâls dal pazient.
Cualchi cure comun e inclût:
1. Vigjilance ative: Cheste metodiche e compuarte il monitorâ di dongje il cancar cun controi e provis regolârs, pluitost che scomençâ subite il tratament.
Al pues jessi adat ai oms cun un piçul risi di tumôr de prostate.
2. Chirurgjie: une prostatectomie e je une procedure chirurgjiche par rimovi la glandule de prostate.
Al pues jessi fat cun la operazion vierte o laparoscopic (cun piçulis incisions e imprescj specializâts).
3. Radioterapie: Chest al dopre lis radiazions ad alte energjie par copâ lis celulis dal cancar.
Al pues jessi soministrât par difûr (di une machine par fûr dal cuarp) o par dentri (par mieç di implants metûts dongje dal tumôr).
4. Terapie hormonâl: Chest tratament al ridûs i nivei dai ormons maschîi (androgens) intal cuarp, che a puedin ralentâ o fermâ la cressite dal tumôr de prostate.
Al pues jessi doprât dome o in cumbinazion cun altris trataments.
5. Chimioterapie: Chest tratament al dopre medisinis par copâ lis celulis dal cancar.
Al pues jessi doprât pal tumôr de prostate avanzât che si è slargjât a altris parts dal cuarp.
6. Imunoterapie: Chest tratament al jude il sisteme imunitari a combati il cancar.
Al pues jessi doprât pal tumôr de prostate avanzât che nol à rispuindût a altris trataments.
7. Terapie mirade: cheste terapie e smire a gjens o proteinis specifics che a judin lis celulis dal cancar a cressi e sorevivi.
Al pues jessi doprât pal tumôr de prostate avanzât che nol à rispuindût a altris trataments.
8. Crioterapie: Chest tratament al dopre un frêt estrem par congela e copâ lis celulis dal cancar.
Al pues jessi doprât pal cancar de prostate in stadi iniziâl o par cancers che a son tornâts dopo altris trataments.
9. Ultrason focalizât a alte intensitât (HIFU): Chest tratament al dopre ondis sonoris di alte frecuence par scjaldâ e distruzi lis celulis dal cancar.
Al pues jessi doprât pal cancar de prostate in stadi iniziâl o par cancers che a son tornâts dopo altris trataments.
10. Aspettative vigjilante: cheste metodiche e compuarte il monitorâ di dongje il cancar cun controi e provis regolârs, ma cence scomençâ il tratament fin che i sintoms no comparissin o no cambiin.
Al pues jessi adat par i oms plui vecjos cun tumôr de prostate che al cres a planc e cun altris malatiis seriis.
Al è impuartant di discutisi di dutis lis opzions di cure cuntun grup di assistence sanitarie par determinâ la miôr maniere di fâ par ogni câs individuâl.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Disclaimer: medicâl']
['Chest sît web al è furnît dome par fins educatîfs e informatîfs e nol è une consulence o un servizi professionâl.']
['Lis informazions furnidis no àn di jessi dopradis par diagnosticâ o curâ un probleme di salût o une malatie, e chei che a vuelin une consulence mediche personâl a àn di consultâ un miedi autorizât.']
['Par plasê note che la rêt neuronâl che a gjenere lis rispuestis aes domandis, e je imprecise soredut cuant a si trate di contignûts numerics.']
['Cîr simpri la consulence dal to miedi o di un altri professionist in materie di salût a rivuart di une malatie. No sta mai dismenteâ la consulence di un miedi professionist o intardâti a cirîle par vie di alc che tu âs let su chest sît. Se tu pensis di vê une emergjence mediche, clame il 911 o va tal pronto socorso plui dongje.']
['Disclaimer: copyright']
['Il Digital Millennium Copyright Act dal 1998, 17 U.S.C. § 512 (il DMCA) al proviôt un ricors pai proprietaris di copyright che a crodin che il materiâl che al comparìs su Internet al violi i lôr dirits sot la leç sul copyright dai Stâts Unîts. ']
['Se tu crodis in buine fede che cualsisei contignût o materiâl disponibil in conession cul nestri sît o i nestris servizis al violi il tô copyright, tu (o il to agjent) tu puedis mandânus une notifiche domandant la rimozion dal contignût o dal materiâl, o il bloc dal acès. ']
['I avîs a àn di jessi mandâts par scrit vie e-mail (cjale la sezion "Contat" par vê l\'indiriç e-mail). ']
['La DMCA e domande che la tô notifiche di violazion dal copyright e vedi dentri chestis informazions: (1) descrizion dal lavôr protet dal copyright che al è ogjet de violazion rivendicade; (2) descrizion dal presunt contignût che al è une violazion e informazions suficientis par permeti di cjatâ il contignût; (3) informazions di contat, includût la tô direzion, numar di telefon e pueste eletroniche; (4) une declarazion di buine fede che il contignût al no è autorizât dal proprietari dal copyright, o dal so agjent, o par vie di une leç; ']
['5) une declarazion di bande tô, firmade sot pena di falsetât, che lis informazions inte notifiche a son veris e che tu âs la autoritât par fâ valê i dirits di autôr che a son stâts violats;']
['e (6) une firme fisiche o eletroniche dal titulâr dal copyright o di une persone autorizade a agjî par cont dal titulâr. ']
['Se no tu âs dutis lis informazions parsore, al podarès intardâ il tratament dal to reclam.']
['Contatât']
['Par plasê mandinus une e-mail cun ogni domande / sugjeriment.']
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['A rivuart']
['BioMedLib al dopre ordenadôrs automatics (algoritmi di aprendiment de machine) par gjenerâ cubiis di domandis e rispuestis.']
['Si scomence cun 35 milions di publicazions biomedichis di PubMed/Medline. e ancje lis pagjinis web di RefinedWeb.']
